| Name | Title | Contact Details |
|---|
Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing. Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API Manufacturing supports the chemical development and cGMP manufacture of complex API, including potent, controlled substances, biologics, peptides, steroids, and cytotoxic compounds. Drug Product Manufacturing supports drug product development through commercial scale production of complex liquid-filled and lyophilized parenteral formulations.
Brain Cells is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Locana is a RNA-targeting gene therapy company
PaxVax is a privately held, fully integrated vaccine company, based in Redwood City, California, USA. Established in 2007, in response to the global threat of the H5N1 pandemic, our founders set out to develop and commercialize an innovative vaccine technology in a socially responsible manner for global impact. Our founding principles were to enable geographically distributed manufacturing of affordable, self-administered oral vaccines against infectious diseases such as influenza. Since then, we have expanded our capabilities and technologies to address unmet vaccine needs against endemic diseases in developing countries, for travelers to disease-laden areas and in biodefense. Our clinical stage portfolio today includes vaccine candidates for cholera, avian influenza (H5N1), anthrax, and HIV. We are committed to providing both attractive financial returns and social returns, without a significant trade-off between the two. As a double bottom line business, we will measure our financial success in terms of return on equity and we will assess our social returns by access to our vaccines globally, particularly to the poor and otherwise disenfranchised. We strive to develop and deliver vaccines that are affordable and deliverable anywhere in the world regardless of the state of medical infrastructure or supply chains. We utilize investment capital as well as R&D grants and contracts to fund the development of our vaccines. We exploit the inherent synergies in our proprietary oral vaccine technology platform to research and develop multiple vaccine candidates in a timely and capital efficient manner. We strive to make an impact on infectious disease morbidity and mortality throughout the world and on the global vaccine industry through our successes. To date, we have raised more than $75 million (USD) from investors including Ignition Ventures, Ignition Growth and the Wellcome Trust. We are supported by R&D grants and contracts from the U.S. National Institutes of Health (NIH) through both its National Institutes of Allergy and Infectious Diseases (NIAID) and Division of AIDS (DAIDS) as well as the Bill & Melinda Gates Foundation. Our most advanced vaccine is a single dose oral cholera vaccine, which entered final or Phase III clinical trials, and whose study should be completed in 2014. Following this candidate is a vaccine ready for Phase II (Pandemic Influenza), two caccines in current Phase I studies (HIV and anthrax), and multiple candidates in preclinical research (HSV, dengue, malaria). PaxVax is headquartered in Redwood City, California and is incorporated in Delaware. Our laboratory and manufacturing facilities and the majority of our 80 employees are located in San Diego, California.
Better chemistry committed to the world`s biggest problems